[188Re]Re-MAE3-DOTA-FAPI

N/A

Report date: 2025/11/20 16:02:56

NME

Base Information

Drug Name[188Re]Re-MAE3-DOTA-FAPI

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Rhenium > 188ReRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionFibroblast activation protein alpha modulators

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesBeijing Changping Laboratory

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Changping Laboratory

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A